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Abstract
Blocking the action of inhibitory molecules at sites of central nervous system injury has been proposed as a strategy to
promote axonal regeneration and functional recovery. We have previously shown that genetic deletion or competitive
antagonism of EphA4 receptor activity promotes axonal regeneration and functional recovery in a mouse model of lateral
hemisection spinal cord injury. Here we have assessed the effect of blocking EphA4 activation using the competitive
antagonist EphA4-Fc in a rat model of thoracic contusive spinal cord injury. Using a ledged tapered balance beam and
open-field testing, we observed significant improvements in recovery of locomotor function after EphA4-Fc treatment.
Consistent with functional improvement, using high-resolution ex vivo magnetic resonance imaging at 16.4T, we found
that rats treated with EphA4-Fc had a significantly increased cross-sectional area of the dorsal funiculus caudal to the
injury epicenter compared with controls. Our findings indicate that EphA4-Fc promotes functional recovery following
contusive spinal cord injury and provides further support for the therapeutic benefit of treatment with the competitive
antagonist in acute cases of spinal cord injury.
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Introduction
Injuries to the spinal cord result in the apoptosis and necrosisof damaged nervous tissue as well as damage to ascending and
descending myelinated nerve tracts. Subsequent to the primary
damage caused by the initial mechanical injury, further cell death
and axonal damage are caused by excitotoxic, ischemic, and in-
flammatory cascades. As the adult mammalian central nervous
system (CNS) has limited inherent capacity to regenerate and restore
functional connectivity across the injury site, traumatic spinal cord
injury (SCI) often results in permanent deficits in movement, sen-
sation, and autonomic functions at and below the level of the injury.
There are now numerous reports showing that repulsive guidance
factors are upregulated following SCI. At the lesion site, factors such
as Nogo (Reticulon 4), repulsive guidance molecule, chondroitin
sulphate proteoglycans, semaphorins, slits, and Eph receptors are
thought to actively inhibit the regeneration of CNS axons, and,
therefore, are current targets for possible therapies to treat SCI.1–6
The Eph:ephrin (receptor:ligand) system is known to play an
important role in spinal cord development as well as injury.
Members of both the Eph receptor and ephrin ligand families are
divided into two subgroups (A and B) with each group showing
high intra- but not inter-class affinity.7,8 Of the receptors, EphA4 is
notable, as it is capable of interacting with ligands from both
subgroups.7,8 EphA4 is known to be involved in the formation of
the major commissures of the brain, patterning of the corticospinal
tract, and creation and/or wiring of the central pattern generator.9–11
Previous research has shown that EphA4 and its ligands are upre-
gulated following injury to the spinal cord and act to prevent axonal
regeneration.12–15 We, and others, have found using rodent models
of transectional SCI, that either genomic deletion or competitive
antagonism of EphA4 leads to axonal regeneration and significant
functional recovery.16–18 Given the therapeutic potential of EphA4
antagonism, we have expanded our investigation of EphA4-Fc
treatment to a rat model of contusive SCI: a model more relevant to
human SCI, as it replicates many pathological features typical of
crush or fracture injuries, such as acute edema and chronic syrin-
gomyelia.
Magnetic resonance imaging (MRI) is an integral component of
the diagnosis and management of human SCI, as it provides a
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noninvasive method to assess the severity of the injury and identify
many of the associated pathological changes, including atrophy,
hemorrhage, edema, and cyst/syrinx formation.19–21 It is also a
valuable tool for assessment of animal models of SCI, as the data
can be easily translated and compared with human SCI MRI data.
Diffusion tensor imaging (DTI), a method to quantify the magni-
tude and direction of water movement, is increasingly being used
to examine pathway integrity after traumatic injuries and other
degenerative diseases affecting the CNS.22,23 Changes detected
by MRI and DTI following SCI are thought to provide good cor-
relation with anatomical, immunohistochemical, and behavioral
observations.24–26
In the present study, we delivered the recombinant fusion protein
EphA4-Fc to rats following a moderate force-controlled (150
kdyne) contusive injury to the lower thoracic spinal cord. Our
results revealed that EphA4-Fc promotes improvements in both
locomotor performance and spinal cord structure after contusive
injury, providing further evidence that EphA4-Fc is a therapeutic
candidate for the treatment of human SCI.
Methods
Protein expression and purification
Ephrin A4-Fc, comprised of the extracellular domain of human
ephrin A4 (amino acids 1–166 of NP_005218.1) fused to the Fc
region of human IgG1 (amino acids 99–330 of P01857.1), was
generated and purified as previously described.18,27 To minimize
the possibility of an Fc-mediated response in the rat, we used a
recombinant Fc protein, which consisted of the extracellular do-
main of human EphA4 (amino acids 1–546 of NP_004429.1) fused
to the human Fc domain of IgG4 (amino acids 99–327 of
P01861.1). EphA4-Fc was cloned into the mammalian expression
vector pcDNA3.1 (Invitrogen, Life Technologies). The nucleotide
sequence of the construct was verified by sequencing both strands
using BigDye Terminator Version 3.1 Ready Reaction Cycle
Sequencing and an Applied Biosystems 3130xl Genetic Analyzer.
Large-scale preparations of plasmid DNA were conducted using
QIAGEN Plasmid Giga Kits according to the manufacturer’s
instructions.
Transient transfections of the EphA4-Fc expression plasmid
using FreeStyle 293-F cells were performed using 293fectin
transfection reagent (Invitrogen, Life Technologies) according to
the manufacturer’s instructions. Cells (1000mL) were transfected
at a final concentration of 1 · 106 viable cells/ml and incubated in a
2L Cellbag (GE Healthcare Life Sciences) for 6 days at 37C in 8%
CO2 on a 2/10 Wave Bioreactor system or 20/50 (GE Healthcare).
The culture conditions were 35 rocks/min with an angle of 8.
Pluronic F68 (GIBCO, Life Technologies), to a final concentra-
tion of 0.1% v/v, was added 4 h post-transfection. At 24 h post-
transfection, cell cultures were supplemented with LucraTone
Lupin (Millipore) to a final concentration of 0.5 % v/v. The cell
culture supernatants were harvested by centrifugation at 2500 rpm
and were then passed through a 0.45 lm filter (Nalgene) prior to
purification.
Conditioned media containing EphA4-Fc (10–15 L) was con-
centrated 10-fold using tangential flow filtration (Centramate, Pall
Corporation, USA) with a 900 sq cm, polyether sulfone membrane
(Pall Corporation, USA) as per themanufacturer’s instructions. The
conditioned media was diafiltered into phosphate-buffered saline
(PBS) post concentration.
The concentrated conditioned media was applied to a 10mL
Protein A affinity chromatography column (mAb select, GE,
Sweden) by gravity feed, and washed with 250mL PBS. Bound
EphA4-Fc was eluted with 0.1M citrate buffer (pH 3.0) and 10mL
fractions were neutralized with 2mL 2M Tris buffer (pH 8.0).
Fractions were loaded onto an ion exchange resin (HiLoad Q 26/10,
GE, Sweden) using an AKTA explorer High-performance liquid
chromatography (HPLC) at a flow rate of 10mL/min with a 30min
linear gradient between Tris buffer (20mM pH 8) and Tris buffer
containing sodium chloride (2M). Absorbance at 280 nm was used
to monitor and collect peak fractions.
Size exclusion was used to separate the dimeric EphA4-Fc
protein from other molecular weight species. Typically a Superdex
200 (47/50) column was used to purify the EphA4-Fc protein in
PBS containing azide. Fractions were selected based on the ob-
servation of a single species in an analytical size exclusion column
(Superose 200 3.2/30). Samples were subsequently dialyzed into
mouse tonicity (MT)-PBS using a 30mL cassette slidalyzer.
(Thermo Fisher Scientific Inc., USA).
The final pool of EphA4-Fc was generated after final quantita-
tion and endotoxin testing. Endotoxin levels were quantitated using
a lipopolysaccharides (LPS) kit based on Pyrchrome chromogenic
endotoxin assay (Associates of Cape Code Inc., USA) as per
manufacturer’s instructions. Protein quantitation was calculated
based on 1.0 absorbance unit at 280 being equivalent to 1.3mg/mL.
Purity was based on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and proteins visualized by coomassie
stain. Binding properties of the recombinant proteins were
confirmed using real time surface plasmon resonance analysis as
described previously.27,28
Western analysis of EphA4 blocking and activation
The cDNA encoding mouse EphA4 (nucleotides 55–3024;
NM_007936.3) was cloned into the expression vector pEF-BOS29
and transfected into Chinese hamster ovary (CHO) cells. A stably
expressing EphA4 clonal line was generated and grown in hu-
midified 5% CO2 at 37C in Dulbecco’s Modified Eagle Medium
(DMEM)/F12 media supplemented with 10% fetal bovine serum,
penicillin (100U/mL) and streptomycin (100lg/mL). For EphA4
activation assays (n= 3), 80–90% confluent cultures were serum
starved for 2 h. EphA4-Fc was added at 2, 5, or 10lg/mL 30min
before ephrin A4-Fc was added at 1lg/mL. After 30min activation
with ephrin A4-Fc, cells were lysed in radio immunoprecipitation
assay (RIPA) buffer (150mM sodium chloride, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50mM
Tris, pH 8) with sodium orthovandate (1mM), phenylmethane-
sulfonyl fluoride (1mM) and Complete Protease Inhibitor Cocktail
(1 · ; Roche Applied Science). Lysates were clarified by centrifu-
gation at 14,000 relative centrifugal force (rcf) for 10min at 4C,
and an estimate of the protein concentration was determined using a
bicinchoninic acid assay (Pierce Biotechnology, Inc.). Reduced
protein (50lg) was separated by electrophoresis (4–12% SDS-
PAGE, Novex NuPage, Invitrogen) and transferred onto Im-
mobilon FL membrane (Millipore). Membranes were blocked with
5% skim milk powder in phosphate-buffered saline, 0.02% Tween
20 (PBST) for 1 h. Primary antibodies (mouse anti-EphA4, ECM
Biosciences; rabbit anti-phosphoTyr602-EphA4, ECM Bios-
ciences) were allowed to bind overnight in 5% skimmilk powder in
PBST at 4C. After washing with PBST, bound antibodies were
detected using IRDye secondary reagents (Li-COR Biosciences)
and bands were detected using the Odyssey system (Li-COR
Biosciences). Absolute integrated intensity values were extracted
and adjusted for background values, and the intensity of phos-
phorylated EphA4 was normalized to total EphA4 levels. Relative
values were expressed as a percentage of the mean untreated value.
Surgical procedures
All animals were treated in accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientific Purposes,
and ethical approval was obtained from the University of
Queensland Anatomical Biosciences Ethics Committee.
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Adult female Wistar rats (10–12 weeks old, 200–250 g) were
housed in groups of two or three animals and maintained on a 12 h
light:12 h dark cycle with ad libitum access to food and water. Prior
to surgery, animals were acclimated to handling and the experi-
mental environments for 2 weeks. Rats were anesthetized with a
combination of ketamine and xylazine (100mg/kg and 10mg/kg,
respectively). An incision was made through the skin and muscles
overlying the thoracic spine to expose the T9–T11 vertebrae. The
spinal cord (approximate spinal level T11/12) was exposed by a
dorsal laminectomy at T10. The spine was then immobilized using
two Adson forceps, placed at T9 and T11, respectively. A force-
defined contusive injury of 150 kdyne was inflicted using the
Infinite Horizons impactor device.30 Following impact, the mus-
culature and skin were closed in separate layers with sutures, after
which the animals were returned to their home cage to recover.
Experimental rats were treated with antibiotics (Baytril, 2mg/kg)
and pain relief (Torbugesic, 2mg/kg) for 48 h. Bladders were
manually expressed twice daily for up to 2 weeks, or until bladder
control was recovered. One animal receiving treatment with 5mg/
kg EphA4-Fc died just prior to perfusion. Postmortem examination
did not reveal any specific cause of death related to the SCI or
treatment. As such, we included its behavioral data for analysis, but
could not include it for MRI or DTI analysis.
EphA4-Fc delivery
Animals were randomized prior to recovery from anesthesia and
given their first treatment 2h after surgery. All treatments were
delivered by intraperitoneal injection. Animals received initial
doses of 40mg (n= 11), 10mg (n = 12) or 2mg (n = 10) EphA4-Fc
per kg body weight, whereas controls received injectable saline as
the vehicle (n= 12). Animals then received additional EphA4-Fc or
saline injections at half the original dose (i.e., 20mg, 5mg, or 1mg
per kg body weight) every second day from 24 h post-injury up to
14 days post-injury (DPI). Researchers involved in assessing injury
outcomes were blinded to the treatment.
Circulating EphA4-Fc in sera detected
by enzyme-linked immunosorbent assay (ELISA)
Serum levels of circulating EphA4-Fc were measured on days 7,
14, and 21 after injury by sandwich ELISA. Briefly, 200–300lL of
blood was collected from the tail and allowed to clot for 30min at
room temperature. Serum was separated by centrifugation at 1500g
for 10min and stored at - 80C prior to analysis. High-capacity
binding ELISA plates (Greiner) were coated with a monoclonal
antibody targeting the extracellular domain of EphA4 and blocked
with 1% bovine serum albumin. Triplicate samples of diluted se-
rum were applied to the plates and the presence of the recombinant
EphA4-Fc was detected using a horseradish peroxidase (HRP)-
conjugated goat anti-human IgG Fc polyclonal antibody and the
SigmaFAST o-phenylenediamine dihydrochloride (OPD) sub-
strate (Sigma Aldrich). A standard curve was generated using pu-
rified EphA4-Fc at concentrations between 0 and 200 ng/mL.
Ledged tapered balance beam task
This task requires rats to cross an elevated, tapered (6.5–2.5 cm)
beam, 1.4m in length, with support ledges on either side at a height
2 cm lower than the upper surface of the beam. Rats were trained to
cross the beam (four trials per day) on the 2 days immediately prior
to testing at 120 days after injury, that is, the end of the experiment
period. The distance to first misstep, where the animal failed to step
on the upper surface, and the total number of substantial missteps
(i.e., where the animal failed to straddle the beam or fell from the
beam) over four trials were recorded and averaged. This assay
provides a quantitative measure of functional deficits, specifically
in relation to skilled paw placement, coordination, and balance of
impaired rats.31,32
Open-field locomotor performance
We assessed and scored open-field locomotor ability according
to the 21 point Basso, Beattie and Bresnahan (BBB) locomotor
rating scale.33 This nonlinear scale was developed to discriminate
between functional outcomes following SCI in rats. It is broken up
into three divisions, with scores of 0–7 describing joint and limb
movement, 8–14 describing weight-supported stepping and fore-
limb–hindlimb coordination, and 15–21 describing finer aspects of
locomotion that include toe clearance and paw rotation.33 Animals
were assessed twice a week for the first fortnight, once a week for
the next 6 weeks, and once at the end of the experiment (120 DPI).
Scoring was performed over a 4min period by two blinded asses-
sors; the average score for each animal was used for statistical
analysis.
MRI
Following the final behavioral tests at 120 days after injury, rats
were deeply anesthetized with an overdose of sodium pentobarbital
(300mg/kg; Virbac), before being transcardially perfused with cold
PBS followed by 4% paraformaldehyde in PBS. The vertebral
column was dissected and post-fixed in 4% paraformaldehyde in
PBS for 48 h at 4C. For ex vivoMRI scans, vertebral columns were
extensively washed in PBS and subsequently placed in a 0.2%
solution of Magnevist (gadopentetate dimeglumine; Bayer
Healthcare) for at least 48 h, to enhance contrast between gray and
white matter. Samples were next immersed in perfluorocarbon
solution (Fomblin Y06/06, Solvay Solexis, Italy) for imaging. We
examined six to eight animals from each treatment group by con-
ventional high-resolution MRI; additional DTI analysis was per-
formed for rats from the vehicle, 5mg/kg EphA4-Fc, and 20mg/kg
EphA4-Fc treatment groups. Three 24-week-old uninjured controls
were examined in an identical fashion for both MRI and DTI to
obtain baseline measures.
MRI was performed using a Bruker 16.4T small animal MR
imaging system, with a vertical wide bore that was equipped with a
Micro2.5 gradient set (Karlsruhe, Germany; M2M Imaging, Aus-
tralia) and 15mm linear saw coil (M2M Imaging). High-resolution
imaging was performed using Bruker gradient echo fast low angle
shot magnetic resonance imaging (FLASH) sequence with TR/
TE= 40/7.5ms, 25 degree flip angle, four excitations and, 50 kHz
spectral width. Images were acquired with a 28 · 12.8 · 12.8mm
field-of-view with 560 · 420 · 420 matrix to produce a 30· 30lm
coronal plane and 50lm slice resolution.
Following the conclusion of high-resolution MRI, spinal cords
were dissected from the vertebral column. DTI was performed on
the 16.4T MR system using a 10mm Quadrature coil (M2M Ima-
ging), with the following DTI-spin echo imaging parameters: TR/
TE= 400/24ms, d/D= 2/15ms, 2 excitations, 6 non-collinear diffu-
sion encoding directions ([1,1,0],[1,0,1],[0,1,1],[-1,1,0],[1,0,-1],
[0,-1,1]) and 1 B0 image. Images were acquired using a 22.3·
5· 5mm field-of-view with a 420· 96· 96 matrix to give 50lm
three dimensional (3D) isotropic resolution.
MRI and DTI analysis
Each region of interest (ROI) corresponding to the dorsal funic-
ulus, gray matter, ventrolateral white matter, damaged tissue (atyp-
ical appearance compared to normal, uninjured tissue), and cystic
cavitation was outlined using the closed polygon ROI tool in Osirix
v3.9.234 or ImageJ in coronal slices that were spaced 0.5mm apart
over a 10mm segment of the spinal cord. For uninjured animals,
ROIs were examined every 1mmover the same distance. For injured
animals, the coronal slice that showed the smallest cross-sectional
area of the spinal cord was defined as the epicenter. In all cases, this
was located within 1mm of the junction of the T9 and T10 vertebral
bodies. The 10mm field of view covered at least two vertebral levels
containing the full extent of the cystic cavity and the vast majority of
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observable pathology. The areas for each region were extracted for
statistical evaluation and graphical analysis.
For DTI analysis, data reconstruction and fiber tracking were
performed using Diffusion Tracker v0.6.0.1.35 The default 25 de-
gree angle threshold was increased to 35 degrees. This angle
threshold allowed tracking up to 35 degrees and facilitated tracking
at and near the injury epicenter. Ordered eigenvalue tensor pa-
rameters (k1, k2, and k3) were determined. The output from Dif-
fusion Tracker was then imported into TrackVis v0.5.1.35 The
selection of coronal slices paralleled the MRI analysis. For DTI,
ROIs corresponding to the dorsal funiculus were manually outlined
from the diffusion weighted image every 0.5mm over 10mm (in-
cluding uninjured animals), centered at the epicenter (least cross-
sectional area). Where the dorsal column was not easily identifiable
because of tissue damage, tracks to show connectivity between
ROIs were generated from rostral or caudal ROIs to aid selection.
For each ROI, cross-sectional area and mean values of apparent
diffusion coefficient (ADC), axial diffusivity, radial diffusivity, and
fractional anisotropy (FA) were extracted. Diffusion along the
principal axis of the diffusion ellipsoid was defined as axial diffu-
sivity (Djj= k1) and radial diffusivity as the average of the two minor
eigenvalues [Dt= (k2+ k3)/2]. To quantify the degree of aniso-
tropic diffusion, fractional anisotropy was calculated fFA¼p
1=2[
p
((k1 k2)2þ (k1k3)2þ (k2 k3)2]=p[k21þ k22þ k23]g. A
FA value of 0 indicates complete isotropic diffusion and a value of
1 indicates diffusion in one direction only (complete anisotropy).
Sensory testing
Spinal reflex sensitivity in SCI rats was determined using the
Randall–Selitto deep pressure assay36 and the von Frey assay2 at
120 days following the injury. The Randall–Selitto and von Frey
tests were conducted on different days. Each assay was performed
in triplicate on both the left and right hindpaws, with 10–15min
between individual measurements; the values were then averaged.
For the Randall–Selitto test (Analgesy meter LE7306, Harvard
Apparatus), rats were gently restrained by hand and the maximum
tolerated pressure on the pad of the hindlimb (3mm diameter blunt
tip) that caused either a voluntary withdrawal reflex of the hindlimb
or vocalization was defined as the pain threshold. Sensitivity to
punctate stimulation was determined in the same manner using an
electronic von Frey apparatus (EVF3, Bioseb Instruments).
Statistical analysis
Results are expressed as arithmetic mean – standard error of
the mean (SEM). Data sets were examined for statistically sig-
nificant differences between treatment groups using standard
tests incorporated in GraphPad Prism v5.0. Analyses included
unpaired t test for direct comparisons between two groups, one
way and two way ANOVAs for multiple groups, and longitu-
dinal analyses with appropriate post-hoc testing. Significance for
specific locomotor outcomes in the open-field assay (BBB) and
ledged balance beam assay were determined using receiver-
operator characteristic (ROC) curve analysis and tested by
Fisher’s exact test. A p < 0.05 was considered significant for all
statistical analyses.
Results
Soluble EphA4-Fc prevents ephrin-induced
activation of EphA4
To verify that EphA4-Fc could block ephrin-dependent EphA4
activation, we compared phosphorylation levels of EphA4 fol-
lowing treatment with 1) ephrin A4-Fc, 2) EphA4-Fc, and 3) ephrin
A4-Fc and EphA4-Fc. We showed that 1lg/mL ephrin A4-Fc
activated EphA4 and caused a significant increase in EphA4
phosphorylation, and that the addition of EphA4-Fc effectively
blocked ephrin-dependent phosphorylation ( p< 0.001; Fig. 1A, B).
Importantly, blocking of EphA4 activation was achieved at con-
centrations of EphA4-Fc similar to that detected in rat serum fol-
lowing treatment with 5mg/kg and 20mg/kg EphA4-Fc. Two
FIG. 1. EphA4-Fc prevents ephrin-induced phosphorylation of EphA4. (A) Chinese hamster ovary (CHO) cells expressing EphA4
were blocked with EphA4-Fc prior to the addition of ephrin A4-Fc. Lysates were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and bands specific for total EphA4 and phosphorylated EphA4 detected. (B) Quantification of band
densities shows that only in the absence of EphA4-Fc could ephrin A4-Fc significantly increase the phosphorylation of EphA4 above
basal levels (one-way ANOVA with Bonferroni’s post-test). Blocking with EphA4-Fc prevented ephrin-induced phosphorylation of
EphA4. ***p< 0.001.
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weeks following SCI, the circulating levels of EphA4-Fc were re-
corded to be 3.5 – 1.1 lg/mL and 24– 3.9 lg/mL for the 5mg/kg
and 20mg/kg groups, respectively. EphA4-Fc was not detected
above background levels in rats treated with 1mg/kg EphA4-Fc.
To check that the naı¨ve rat did not generate an immune re-
sponse to the EphA4-Fc fusion protein, EphA4-Fc-treated rats
were examined for the presence of rat antibodies that targeted
EphA4-Fc. One rat (from the 1mg/kg treatment group) showed an
immune response and performed extremely poorly in the balance
beam task. This rat was excluded from all tests measuring loco-
motor performance.
EphA4-Fc improved functional outcome
following contusive SCI
We have previously shown, using a mouse model of lateral
hemisection SCI, that administration of EphA4-Fc at 20mg/kg
promoted functional recovery and axonal regrowth.18 Although the
lesion model is useful for studying regeneration, it has limited
relevance to the majority of human SCI cases. To assess the ef-
fectiveness of EphA4-Fc treatment in the present study, we used a
rat model of contusive SCI, as it replicates many of the pathological
features seen in human SCI cases.
We used the ledged tapered beam assay to obtain a quantitative
measure of skilled limb placement. This assay interrogates aspects
of balance and coordination of rats as they cross a narrowing, raised
beam, and has been previously used to measure functional differ-
ences following SCI.31,37 At 120 days following the injury, we
observed a dose-dependent improvement in rats treated with
EphA4-Fc (Fig. 2A). Rats treated with 5mg/kg and 20mg/kg tra-
versed 106 – 7.5 cm and 118– 5.7 cm, respectively, of the 140 cm
ledged tapered beam without error, as compared with the vehicle-
treated group, which averaged only 76.4 – 11.3 cm. Although rats
treated with 1mg/kg EphA4-Fc did not differ significantly from the
vehicle-treated group in the distance traveled until first misstep
(94 – 10.7 cm; Fig. 2A), they recorded significantly fewer falls or
serious missteps compared with the vehicle-treated group
( p< 0.05; Fig. 2B).When the data from all treated rats were pooled,
an overall positive effect of EphA4 blocking was observed. EphA4-
Fc-treated rats were able to cross a significantly greater distance of
the beam without error than were rats treated with the vehicle alone
( p< 0.01; Figure 2C). Response to EphA4-Fc treatment was also
assessed using a second means, namely an ROC. Using this model,
we determined 100 cm to be the threshold at which a positive re-
sponse to treatment could be recorded. If animals crossed less than
this distance before first misstep, a negative response to treatment
was recorded. Of the animals that received EphA4-Fc, 64% (21/33)
recorded a positive response, compared with only 25% (3/12) of
vehicle-treated animals. Overall, using this method of analysis,
EphA4-Fc-treated animals performed significantly better than ve-
hicle-treated rats on the ledged balance beam ( p= 0.0406, Fisher’s
exact test).
At 120 DPI, we assessed the performance of EphA4-Fc-treated
and vehicle-treated rats in the open field using the BBB locomotor
rating scale (Fig. 3). All treated groups showed mean BBB scores
higher than that of the control group; however, because of the size
and variation within the groups, this improvement was only sta-
tistically significant for rats treated with 1mg/kg EphA4-Fc
( p< 0.01; Fig. 3A). When data from all EphA4-treated rats were
pooled and compared with controls, at 120 days following injury, a
significant improvement in functional recovery was observed
( p< 0.05; Fig. 3B). Using ROC curve analysis, a BBB score> 12
(correlating to occasional coordination and weight-supported
plantar stepping or better) was determined as the minimum score
for a positive response to treatment. A significantly greater number
of EphA4-Fc treated rats (91%, 30/33) recorded a positive result to
treatment when compared with the vehicle-treated rats (58%, 7/12)
( p= 0.0224, Fisher’s exact test).
MRI and DTI showed structural improvement
following treatment with EphA4-Fc after SCI
Next, at 120 days following injury, MRI and DTI data were
collected and used to assess whether EphA4-Fc had any positive
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FIG. 2. EphA4-Fc improves coordination and balance after contusive spinal cord injury (SCI). (A) At 120 days following injury,
animals treated with 5mg/kg or 20mg/kg EphA4-Fc showed a significant improvement in their ability to cross the ledged, tapered beam
before misstepping (one-way ANOVA with Dunnett’s post-test). (B) Rats treated with 1mg/kg or 20mg/kg EphA4-Fc had significantly
fewer falls than animals treated with the vehicle (one way ANOVA with Dunnett’s post test; p = 0.074 for animals treated with 5mg/kg
EphA4-Fc, unpaired t test). (C) When data from all EphA4-Fc treatment groups were pooled, the mean distance before a misstep for
animals treated with EphA4-Fc was significantly greater than for animals treated with vehicle alone (unpaired t test). *p< 0.05,
**p< 0.01; d.p.i.: days post-injury.
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structural effect on the injured spinal cord. As the images obtained
were of very high resolution, it was possible to accurately dis-
criminate between different regions of the cord (termed ROIs)
and between normal and damaged tissue. Representative examples
of mid-sagittal views of MRI scans are shown in Figure 4A–D, and
an example of a coronal slice (from Fig. 4B) is shown in Figure 4E
and F.
Overall, we found no significant treatment effect when com-
paring the area of normal tissue at the epicenter in spinal cords
from vehicle- (42.0 – 5.4%, n = 7) and EphA4-Fc-treated rats
(31.9 – 4.8%: 1mg/kg [n= 7]; 43.0 – 4.8%: 5mg/kg [n= 6]; 43.4 –
9.8%: 20mg/kg [n = 8]). To examine the structure of the spinal cord
more closely, we quantified the area within each of the five ROIs,
namely the dorsal funiculus, gray matter, ventrolateral white mat-
ter, cysts, and damaged tissue (Fig. 4). Compared with controls, we
observed a significant increase in the cross-sectional area of the
dorsal funiculus caudal to the lesion epicenter in EphA4-Fc treated
animals ( p < 0.05 at 2.5mm for the 1mg/kg group; p< 0.05 at 1.5
and 2.0mm and p < 0.01 at 2.5mm for the 5mg/kg group; p< 0.05
at 3.0mm for the 20mg/kg group; Fig. 4G–J). No significant dif-
ference in cross-sectional area was observed for the remaining
ROIs; however, 60% (12/20) of the EphA4-Fc-treated rats had
ventrolateral white matter with a greater cross-sectional area than
the maximum cross-sectional area recorded for all vehicle-treated
rats (Supplementary Fig. 1) (see online supplementary material at
http://www.liebertpub.com). Overall, the mean area of the ven-
trolateral white matter was 1.12 – 0.06mm2 for the EphA4-Fc
group and 0.92 – 0.11mm2 for vehicle-treated rats. Although not
significant, these data suggest a trend toward improved structural
integrity following treatment.
Using DTI, we examined spinal cords from the 5mg/kg (n= 8)
and 20mg/kg (n = 6) treatment groups, as these groups showed the
most significant treatment response, and compared them with those
treated with vehicle alone (n= 7). An example of mid-sagittal views
of DTI images, with ROIs highlighted, are shown in Figure 5A–D.
We found that the DTI data confirmed our MRI analysis, as the area
of the dorsal funiculus caudal to the injury site was larger in animals
treated with EphA4-Fc (Fig. 5E). As expected after contusive SCI,
in all animals, that is, both EphA4-Fc- and vehicle treated, a de-
crease in fractional anisotropy was observed throughout the injury
site (Fig. 5F) and increases in ADC and axial and transverse dif-
fusivity were observed at the center of the lesion (Fig. 5G–I).
EphA4-Fc had acute effects on locomotor performance
after contusive SCI
Our observations that rats treated with EphA4-Fc had improved
locomotion and increased cross-sectional area of the dorsal funic-
ulus may indicate preservation of white matter. To assess this
possibility, we analyzed the open-field performance of the injured
rats in the acute phase – 1, 3, and 14 days – following SCI, and
found that the 1mg/kg and 5mg/kg treatment groups performed
significantly better than the control group at all three time points
( p< 0.05 for 1mg/kg and p < 0.01 for 5mg/kg at 1 DPI; p < 0.01 for
1mg/kg and p < 0.05 for 5mg/kg at 3 DPI; p< 0.01 for 1mg/kg and
p < 0.05 for 5mg/kg at 14 DPI; one-way ANOVA; Fig. 6A–C).
These improvements suggest that EphA4-Fc has positive effects in
the acute period after contusive SCI possibly because of preser-
vation, although the exact mechanism is yet to be elucidated.
EphA4-Fc did not increase nociceptive sensitivity
It has previously been reported that small interfering RNA
(siRNA)-mediated downregulation of EphA4 expression increased
the sensitivity of animals to nociceptive pain following SCI.38 To
test for sensory hypersensitivity after EphA4-Fc treatment, we used
the electronic von Frey point stimulation assay (Fig. 7A) and the
Randall–Selitto broad pressure assay (Fig. 7B). Uninjured animals
showed a mean nociceptive response to a force of 22.63g ( – 0.55g
SEM; n = 2) in the von Frey assay and 313.6g ( – 42.63g SEM;
n = 2) for the Randall–Sellito assay. Slightly increased sensitivity in
von Frey thresholds was observed as a result of SCI, which was
independent of treatment; however, none of the treatment groups
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FIG. 3. EphA4-Fc improves open-field locomotor performance after contusive spinal cord injury (SCI). (A) At 120 days following
injury, rats treated with 1mg/kg EphA4-Fc had significantly better Basso, Beattie and Bresnahan (BBB) scores than rats treated with the
vehicle alone (one-way ANOVA with Dunnett’s post-test). (B) When combined, all EphA4-Fc treated animals had significantly better
open-field locomotor performance than did controls (unpaired t test). *p< 0.05, **p< 0.01; d.p.i.: days post-injury.
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differed significantly in their response to the point stimulation assay
when compared with vehicle-treated controls (Fig. 7A). In the
Randall–Selitto test, animals treated with 5mg/kg or 20mg/kg of
EphA4-Fc were less sensitive than vehicle-treated animals to the
broad pressure assay (Fig. 7B), however, their responses were not
significantly different to responses from uninjured animals. As
such, we found no evidence of increased nociceptive sensitivity in
EphA4-Fc-treated animals.
Discussion
In the current study, we assessed the efficacy of EphA4-Fc
therapy in a contusion injury model that more accurately mimics
the pathology associated with the majority of human SCI cases.
Here, we observed significant improvements in the functional
outcomes and identified anatomical changes in the spinal cords
of EphA4-Fc-treated rats compared with vehicle-treated rats.
FIG. 4. MRI analysis shows that the area of the dorsal funiculus is greater following EphA4-Fc treatment after spinal cord injury
(SCI). Examples of high-resolution MRI mid-sagittal views of injured spinal cords from rats treated with (A) vehicle alone (n = 7), (B)
1mg/kg (n = 7), (C) 5mg/kg (n = 6), and (D) 20mg/kg EphA4-Fc (n = 8). (E) Example of a coronal MRI slice (from [B], white line
indicates location), with regions of interest (ROIs) shown in (F). DF: dorsal funiculus; GM: gray matter; VL: ventrolateral white matter;
C: cyst; and D: damaged tissue. (G–I) The area of the dorsal funiculus in rats treated with (G) 1mg/kg, (H) 5mg/kg, and (I) 20mg/kg
EphA4-Fc was significantly greater caudal to the injury epicenter when compared with controls. The area of the dorsal funiculus for rats
treated with the vehicle is shaded to the extent of its standard error of the mean. ( J) A schematic of the increased area of the dorsal
funiculus caudal to the injury epicenter (striped area) in EphA4-Fc-treated rats compared with rats treated with the vehicle alone. Scale
bars for panels (A–D) as indicated in (A), and for (E) and (F) as indicated in (F). *p< 0.05, **p < 0.01, two-way ANOVA with
Bonferroni’s post-test.
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Therapeutic targeting of members of the Eph:ephrin system has
been suggested to have great clinical value. Ephrin-A1-Fc, injected
after myocardial infarction, has shown efficacy in reducing tissue
damage in mice,39 whereas EphA2-Fc reduced tumor burden in a
pancreatic ductal adenocarcinoma model in mice.40 We recently
reported that recombinant protein antagonists of EphA4 (ephrin-
A5-Fc and EphA4-Fc) improved outcomes in a lateral hemisection
model of SCI in mice,18 mirroring the positive effects that were
observed following genetic deletion of EphA4.17 These findings
were accompanied by the observation that mice treated with
EphA4-Fc or ephrin-A5-Fc after SCI showed evidence of axonal
regeneration in the lateral white matter and signs of decreased
gliosis.18 We have also observed a positive response to treatment
with the full-length EphA4-Fc compared with a deletion mutant of
the recombinant EphA4-Fc protein, dLBD-EphA4-Fc, which
lacked the key ligand-binding region (amino acids 20–274 of
NP_031962.2). In a hemisection SCI model in wild-type C57 mice,
we observed axonal regeneration through the lesion site in all
FIG. 5. Diffusion tensor imaging (DTI) analysis shows that the area of the dorsal funiculus is greater following EphA4-Fc treatment
after spinal cord injury (SCI). (A–D) Example of a high-resolution DTI midsagittal images. Examples of the regions of interest (ROIs)
from (A) are shown in (B–D) (rostral to caudal, B: - 2.0mm, C: 0.0mm, D: + 2.0mm). (E) The cross-sectional area of the dorsal
funiculus in the 5mg/kg group was significantly greater 2mm caudal to the injury epicenter, and in the 20mg/kg EphA4-Fc treatment
group, the area was significantly greater 3mm rostral and 2–3.5mm caudal to the lesion epicenter. Quantitative measures of diffusion
(F, fractional anisotropy; G, apparent diffusion coefficient; H, axial diffusivity; and I, transverse diffusivity) reveal an increasing loss of
white matter integrity closer to the lesion epicenter. The vehicle-treated group is shaded to the extent of its standard error of the mean.
Scale bar for (A–D) as indicated in (A). + p< 0.05, *p < 0.05, **p< 0.01, ***p< 0.001, two-way ANOVA with Bonferroni’s post-test.
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animals treated with the full-length protein, but saw no significant
improvement in those treated with the mutated form (unpublished
observation). Given this observation, and the fact that the human
IgG4 has a significantly lower capacity to activate complement and
a significantly lower ability to bind to the Fc gamma receptors, the
probability of observing nonspecific Fc-mediated effects in our
model was low.
Although in vitro data suggest that the major mechanism by
which EphA4-Fc affects axon regeneration in vivo is primarily
through modulation of the Rho-Rac-Cdc42 signaling cascades,17,41
the acute improvements presented here cannot be directly related to
axon regeneration. We did not assess bulk axonal sparing/regen-
eration through anterograde tracing as, unlike the hemisection
model of SCI,17,18 of the axons that traverse the injury site, there is
no way to tell which were spared and which were severed by the
original impact and subsequently regenerated. We therefore opted
for more clinically relevant high-resolution MRI and DTI to assess
tissue integrity, and this assessment provided evidence of the
therapeutic effect of EphA4-Fc administration in moderate con-
tusive SCI.
Our current findings demonstrated that EphA4-Fc therapy re-
sulted in a significant improvement in locomotor ability in rats with
moderate contusive SCI. Modeling contusive injuries in rodents
results in dorsally inflicted injuries and the resultant preservation in
the ventrolateral quadrant of the spinal cord, which contains im-
portant tracts for general stepping and locomotion,42,43 makes the
detection of improvement beyond the considerable degree of
spontaneous recovery after SCI inherently more difficult. The BBB
scoring system had limited capacity to identify improvements in
locomotor ability following EphA4-Fc therapy after contusive SCI;
however, the ledged tapered balance beam task, which assays for
skilled paw placement, balance and coordination, revealed signif-
icant dose-dependent improvements in locomotor performance.
The differences in sensitivity between these two tests is highlighted
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FIG. 6. EphA4-Fc treatment improves open-field locomotor performance in the acute phase after injury. When tested in the open field,
rats treated with 1mg/kg or 5mg/kg EphA4-Fc had significantly higher Basso, Beattie and Bresnahan (BBB) scores than did vehicle-
treated animals (A) 1 day, (B) 3 days, and (C) 14 days after contusive injury (one-way ANOVA with Dunnett’s post-test). *p< 0.05,
**p< 0.01.
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FIG. 7. EphA4-Fc treatment did not affect the nociceptive response to pressure. Treated animals did not show any increase in
mechanical hyperalgesia as tested using the (A) von Frey assay and (B) the Randall–Siletto assay. The animals treated with 5mg/kg or
20mg/kg EphA4-Fc were significantly less sensitive using the Randall–Siletto measure of broad pressure pain (one-way ANOVA with
Dunnett’s post-test). *p < 0.05.
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by the results of the 20mg/kg EphA4-Fc treatment group, which
showed increased area of the dorsal funiculus and significantly im-
proved ability on the ledged tapered balance beam, but no significant
improvement in open field ability as measured by BBB score.
Improvements in the locomotor ability of EphA4-Fc-treated rats
suggest that EphA4-Fc treatment can improve SCI outcomes via
mechanisms other than (or in addition to) restorative regrowth. A
reduction in secondary injury, possibly as a result of a reduction in
the severity of the inflammatory response, and resulting cellular
damage and death, following EphA4-Fc treatment,44 could explain
the acute behavioral improvements observed, and may result in
only small changes in the ventrolateral white matter detected at the
epicenter by MRI.
It is also possible that EphA4-Fc improves synaptic function
and/or plasticity. It has been shown that EphA4-positive neurons
are a major component of the excitatory motor pathway that con-
trols the central pattern generator for locomotion.11 In conjunction
with research that demonstrates that antagonism of EphA4 in-
creases dendritic spine formation,45 antagonizing Eph:ephrin ac-
tivity within or distal to the lesion site may promote dendritic
spinogenesis and synapse formation, thereby improving connec-
tivity and function of the remaining ventrolateral white matter
tracts, improving spontaneous locomotor ability as assessed by the
open-field locomotor task. Our previous reports, however, suggest
EphA4-Fc promotes functional improvements through axonal re-
generation after contusive SCI,18 despite only a marginal decrease
in astrogliosis. Therefore, it is more likely that EphA4 acts in a
similar manner to what we described originally.10 More recent
studies have shown that a lack of EphA4 promotes survival of
motor neurons in the spinal cord of animals with experimental
amyotrophic lateral sclerosis, indicating that blocking EphA4, in
this case, may act to prevent cell death and preserve tissue after
injury.46 Given that the dorsal funiculus is required for voluntary or
skilled locomotor ability,37,47 and our current observations of im-
proved locomotion and larger dorsal funiculus after EphA4-Fc
treatment, future studies will be needed to identify whether this
improvement is caused by axon regeneration or preservation.
Although other studies have used MRI and DTI to examine
SCI,24,48,49 this is the first reporting high-resolution data sets for
MRI (50 lm · 30lm· 30 lm) and DTI (50lm · 50 lm · 50 lm) of
contused rat spinal cords, and the first to use these measures to
assess the effect of EphA4-Fc treatment. We observed a decrease in
fractional anisotropy and an increase in diffusivity within the le-
sion, irrespective of directionality and/or treatment. This indicates
that the white matter within the dorsal funiculus had lost structural
and directional integrity. We also observed a significantly greater
cross-sectional area of the dorsal funiculus through high-resolution
MRI, particularly caudal to the site of injury in EphA4-Fc-treated
groups. Our high-resolution DTI imaging analysis did not, how-
ever, reveal any clear evidence for greater structural tissue integrity
in this area, and the biological significance of this observation
remains undetermined. In contrast to our hypothesis that high-
resolution DTI may detect changes caused by EphA4-Fc treatment,
our results suggest that DTI after contusive SCI, even at high res-
olution, is unlikely to resolve differences in diffusion metrics of the
spinal cord that result from therapeutic intervention. We conclude
that MRI and DTI techniques, although useful for detecting gross
anatomical differences (e.g., tissue sparing), are unlikely to detect
small regenerative responses following therapeutic interventions in
the corticospinal tract at current clinical resolutions, particularly as
recent data suggest that the corticospinal tract does not undergo
retrograde cell death and shows innate sprouting capability.50,51
Induction of central pain syndromes resulting from the patho-
logical sprouting and activation of astrocytes and microglia within
the injured spinal cord (which sensitized the dorsal horn neurons to
excitation through suppression of inhibitory synaptic activity), has
been cited as a potential concern or side effect of regenerative
therapies.52,53 In contrast to a previous study in which EphA4 was
downregulated through siRNA-mediated knockdown,38 we did not
observe any behavior that indicated hypersensitivity in EphA4-Fc-
treated rats using two different assessments of nociceptive sensi-
tivity. In this case, siRNA repression of EphA4, as measured by
semiquantitative polymerase chain reaction (PCR), was only par-
tially successful, and would not prevent all the signaling interac-
tions that can occur. In our case, EphA4-Fc acted as a promiscuous
blocker of most Eph and ephrin interactions, and, as we present
here, did not increase the sensitivity to nociceptive stimuli.
We have previously reported a significant reduction of astrocytic
gliosis in EphA4 null mice following a hemisectional SCI;17 how-
ever, following the same type of injury, wild-type mice showed only
a marginal reduction in gliosis when treated with EphA4-Fc or
ephrin A5-Fc.18 We have recently published findings to suggest that
the absence of a gliotic response in the EphA4-/- mice following SCI
may be the result of strain differences.54 In addition, our MRI and
DTI analyses only detected significant changes in normal white
matter distal to the injury, and did not reveal any significant changes
to lesion areas. As such, we concluded that the EphA4-Fc was un-
likely to affect gliotic scarring, and in the event that it may have
marginal effects, it is unlikely to be detected using MRI analysis.
Conclusion
In summary, the adult mammalian CNS has very limited ability to
regenerate following disease or trauma, and the successful clinical
intervention for SCI remains an elusive goal. Previous research has
identified EphA4 as a key contributor to the lack of regenerative
potential within the CNS. We show here that therapeutic antagonism
of EphA4 with the recombinant protein antagonist, EphA4-Fc, pro-
vides functional benefits after a contusion injury in rats, and research
is now required to elucidate the mechanisms through which EphA4-
Fc may act. We have now shown the therapeutic effectiveness of
EphA4-Fc in an animal model that shares many clinical features of
human cases of SCI, and EphA4-Fc shows continued promise as a
future therapeutic for spinal cord and possibly other neural injuries.
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